0000899243-18-000454.txt : 20180104 0000899243-18-000454.hdr.sgml : 20180104 20180104160525 ACCESSION NUMBER: 0000899243-18-000454 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180102 FILED AS OF DATE: 20180104 DATE AS OF CHANGE: 20180104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Barrowcliffe Susan E. CENTRAL INDEX KEY: 0001664251 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37519 FILM NUMBER: 18510105 MAIL ADDRESS: STREET 1: 8000 MARINA BOULEVARD, SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc. CENTRAL INDEX KEY: 0001631650 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452748244 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 BUSINESS PHONE: (650) 614-5220 MAIL ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 FORMER COMPANY: FORMER CONFORMED NAME: Allergen Research Corp DATE OF NAME CHANGE: 20150123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-01-02 0 0001631650 Aimmune Therapeutics, Inc. AIMT 0001664251 Barrowcliffe Susan E. AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005-1884 0 1 0 0 General Manager, Europe Common Stock, $0.0001 par value 2018-01-02 4 M 0 75000 3.022 A 75000 D Common Stock, $0.0001 par value 2018-01-02 4 S 0 24401 37.1219 D 50599 D Common Stock, $0.0001 par value 2018-01-02 4 S 0 599 37.7785 D 50000 D Common Stock, $0.0001 par value 2018-01-02 4 S 0 24700 37.1264 D 25300 D Common Stock, $0.0001 par value 2018-01-02 4 S 0 300 37.8633 D 25000 D Common Stock, $0.0001 par value 2018-01-02 4 S 0 24400 37.1195 D 600 D Common Stock, $0.0001 par value 2018-01-02 4 S 0 600 37.7533 D 0 D Stock Option (right to buy) 3.022 2018-01-02 4 M 0 75000 0.00 D 2025-05-13 Common Stock 75000 93400 D The sales reported in the Form 4 were effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. The transaction was executed in multiple trades in prices ranging from $36.58 to $37.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. The transaction was executed in multiple trades in prices ranging from $37.70 to $37.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. The transaction was executed in multiple trades in prices ranging from $36.60 to $37.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. The transaction was executed in multiple trades in prices ranging from $37.85 to $37.87, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. The transaction was executed in multiple trades in prices ranging from $36.55 to $37.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. The transaction was executed in multiple trades in prices ranging from $37.65 to $37.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. The option is immediately exercisable in full or in part. The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest on the first anniversary measured from May 1, 2015 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. /s/ Douglas T. Sheehy, as Attorney-in-Fact for Susan E. Barrowcliffe 2018-01-04